The top three pharmacy benefit managers in the US felt the heat at a hearing of the House Oversight Committee, as lawmakers grilled executives over their business practices and accused them
The House Committee on Oversight and Accountability will quiz leaders of pharmacy benefit managers (PBMs) at a hearing next week, amid scrutiny of the sector's role in rising healthcare cos
The Federal Trade Commission in the US is planning to sue the owners of the three largest pharmacy benefits managers (PBMs) for anti-competitive behaviour, on the heels of its damning repor
A long-awaited report from the US Federal Trade Commission (FTC) on pharmacy benefit managers (PBMs) is out – and will make uncomfortable reading for the pharma supply chain middlemen.
Eli Lilly has launched a new website-based access programme for some drugs like its new obesity therapy Zepbound, opening up a new direct-to-consumer (DTC) channel
Senior lawmakers in the US across both sides of the political divide have released a list of measures that they are considering to reduce medicine costs for patients and t
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh